Sangamo Therapeutics ran out of cash. Eli Lilly and Astellas want the science it spent decades building.

The Mission Biopharma SHAKTI scheme, launched in 2026-27, marks an important step in promoting biologics and biosimilars ...

Sangamo Therapeutics, a pioneering gene editing biotech company in the Bay Area, has filed for Chapter 11 bankruptcy protection and agreed to sell some of its programs and platforms to Eli Lilly and ...

Alamo Biologics filed for bankruptcy protection after a trade-secret lawsuit led to a multimillion-dollar collection fight.

Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for ...

Find out more about the wave of biotech rebranding and why a growing number of companies are choosing this path to start ...

Despite its massive $10.5 billion size and 12-drug scope, Pfizer’s oncology deal with Innovent Biologics took less than five ...

Detailed price information for Sangamo Therapeutics Inc (SGMO) from The Globe and Mail including charting and trades.

Stealth BioTherapeutics is looking to put its tumultuous path behind it with a new name. | Stealth BioTherapeutics is looking ...

Of all the decisions that go into a college application, the choice of major is one of the most important yet misunderstood ...

Fermentation startups making food colors, proteins, sweeteners and specialty ingredients are attracting investment, ...

The book presents a diverse array of useful perspectives — though India is not a lone contributor or victim as painted ...